GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial
NCT07613437 on ClinicalTrials.gov · last registry update 2026-05-29
Registered but not yet open, with 200 participants planned. Due to report 14 June 2028, alongside 27 other tracked readouts that quarter. Primary outcome, as filed: Edema extension distance on Day 7. Sponsors move these dates routinely; any movement since this site started watching is listed below.
- Status
- NOT_YET_RECRUITING
- Phase
- P2
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Chinese University of Hong Kong
- Sponsor type
- Other
- Enrollment
- 200
- Started
- 2026-06-15
- Primary completion
- 2028-06-14 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Edema extension distance on Day 7
Conditions studied
Intracerebral Hemorrhage
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.